WallStSmart
ONCY

Oncolytics Biotech Inc

NASDAQ: ONCY · HEALTHCARE · BIOTECHNOLOGY

$0.87
-5.13% today

Updated 2026-06-03

Market cap
$99.80M
P/E ratio
P/S ratio
58.60x
EPS (TTM)
$-0.32
Dividend yield
52W range
$0 – $2
Volume
1.3M

Oncolytics Biotech Inc (ONCY) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-769.00%
ROA
-171.00%
Debt/equity
-0.10x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$0.00$-14.30M
2007$0.00$-15.64M
2008$0.00$-17.55M
2009$0.00$-17.00M
2010$0.00$-19.97M
2011$0.00$-29.04M
2012$4.85M$-36.37M-2.25%-756.22%-749.73%
2013$0.00$-23.53M
2014$0.00$-18.62M
2015$0.00$-13.72M
2016$0.00$-15.14M
2017$0.00$-15.62M
2018$0.00$-17.04M
2019$0.00$-45.55M
2020$0.00$-16.78M
2021$0.00$-20.98M
2022$0.00$-19.08M
2023$0.00$-20.56M
2024$0.00$-31.71M
2025$0.00$-39.46M

Frequently asked questions

How much free cash flow does ONCY generate?

ONCY produced $-27.60M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ONCY's balance sheet healthy?

ONCY holds $7.14M in cash and equivalents against — in long-term debt, on $-5.21M of shareholder equity. That debt is best read against the cash flow the business throws off each year.